ONO-5046, an elastase inhibitor, attenuates liver mitochondrial dysfunction after endotoxin.
OBJECTIVE
To investigate the effect of ONO-5046, an elastase inhibitor, on liver mitochondrial dysfunction after endotoxin administration.


METHODS
Prospective, randomized, controlled animal study.


METHODS
Research laboratory.


METHODS
Male Hartley guinea pigs.


METHODS
Endotoxin shock was induced by intravenous infusion of Escherichia coli lipopolysaccharide endotoxin (50 mg/kg). Six guinea pigs were treated with endotoxin and saline. Twenty-four guinea pigs received 5, 10, and 30 mg/kg/hr of ONO-5046 after endotoxin administration. Six guinea pigs received only saline.


RESULTS
We measured oxygen uptake in state 3 (substrate and adenosine 5'-diphosphate [ADP]) and state 4 (excess substrate, no ADP), as well as the respiratory control ratio (state 3/state 4), adenosine 5'-diphosphate/oxygen ratio (ADP/O), and arterial ketone body ratio. ONO-5046 was dose dependently effective in liver mitochondrial oxidative phosphorylation, such as oxygen uptake in stage 4, respiratory control ratio, adenosine triphosphate synthesis, ADP/O, and arterial ketone body ratio when ONO-5046 was started 30 mins after endotoxin. The administration of 30 mg/kg/hr of ONO-5046 improved mean blood pressure, which had decreased after endotoxin.


CONCLUSIONS
ONO-5046 attenuates the endotoxin-induced liver mitochondrial dysfunctions that may be related to increased liver blood flow.
Kudoh
A
A
Department of Anesthesiology, University of Hirosaki School of Medicine, Aomori, Japan.
Kudoh
E
E
Ishihara
H
H
Matsuki
A
A
D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006168:Guinea Pigs; D007657:Ketone Bodies / Q000378:metabolism; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors*; D008070:Lipopolysaccharides / Q000633:toxicity*; D008107:Liver Diseases / Q000201:enzymology / Q000517:prevention & control*; D008297:Male; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000201:enzymology; D010100:Oxygen / Q000378:metabolism; D010766:Phosphorylation; D012119:Respiration / Q000502:physiology; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D007657:Ketone Bodies; D008070:Lipopolysaccharides; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D000244:Adenosine Diphosphate; C069195:sivelestat; D019272:Leukocyte Elastase; D010100:Oxygen; D005998:Glycine